TSS
MITO

Two Sigma Securities’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

Two Sigma Securities’s Portfolio MITO Stock Details MITO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,851
Closed -$22K – 1929
2020
Q4 		$22K Buy
+14,851
New +$20.8K ﹤0.01% 1599

Other funds holding MITO

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Securities's MITO Position: Q1 2021 in Review

Two Sigma Securities sold out of Stealth BioTherapeutics Corp. ADS (MITO) in Q1 2021, closing a stake of 14,851 shares — an estimated $22K sold.

Two Sigma Securities first reported a position in MITO in Q4 2020 and held it in 1 quarter. The position peaked at $22K in Q4 2020. 13 funds tracked by Wall St. Rank hold MITO as of Q1 2021.

  • Two Sigma Securities reported no remaining Stealth BioTherapeutics Corp. ADS position as of Q1 2021 after selling out during the quarter.
  • Two Sigma Securities sold 14,851 Stealth BioTherapeutics Corp. ADS shares in Q1 2021, an estimated $22K.
  • Two Sigma Securities first reported a position in Stealth BioTherapeutics Corp. ADS in Q4 2020 and held it in 1 quarter.
  • Two Sigma Securities's Stealth BioTherapeutics Corp. ADS position peaked at $22K in Q4 2020.
  • 13 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q1 2021.

Based on Two Sigma Securities's 13F filing for Q1 2021, filed 17 May 2021.